Metabolic health-focused drug developer Kalohexis is eyeing a debut on the public market after confidentially filing for an initial public offering (IPO) – potentially adding it to a growing list of American biotechs that have opted to go public thus far in 2026.
Though the details around the biotech’s public debut remain sparse, the company notes it has submitted a draft registration statement to the US Securities and Exchange Commission (SEC) related to the IPO. Kalohexis is yet to determine how many shares it will offer and at what price upon its potential public market debut.
Kalohexis' proposed IPO comes four months after the clinical-stage biotech spun out of peptide therapeutic specialist Endevica Bio in March 2026, as it looks to progress its range of therapies for both obesity and cancer cachexia.
At the core of Kalohexis’ approach is the melanocortin system, which is involved in balancing energy intake and expenditure, while also regulating appetite and inflammation. By modulating this system through the melanocortin-3 and -4 receptors (MC3R/MC4R), the biotech proposes that it can treat “many metabolic disorders”.
Currently, Kalohexis has two lead, clinical-stage pipeline programmes to its name.
The most developed is mifomelatide, a dual MC3R/MC4R agonist that’s currently in Phase II for the treatment of cancer cachexia in patients with advanced disease. There are currently US Food and Drug Administration (FDA)-approved therapies for this condition, though GDF-15 cytokine-blocking drugs like Pfizer’s ponsegromab and CatalYm’s visugromab are currently in late-stage development for the condition.
Kalohexis is also testing its oral dual MC3R/MC4R agonist, 710GO, in a Phase I trial to determine if it can encourage durable weight loss in obesity, as a report from GlobalData, parent company of Pharmaceutical Technology, estimates that sales in this market alone will reach $173.5bn across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) by 2031.
US IPO flurry continues
Kalohexis’ proposed public market debut comes as 2026 welcomed two record-breaking biotech IPOs.
In April, fellow obesity biotech, Kailera Therapeutics, secured $625m through a record-breaking upsized public offering to help fund the late-stage programme for its lead obesity injectable, ribupatide – which William Blair analysts say “could compete with Zepbound”.
However, Kailera did not hold this record for long, as cancer therapy developer Parabilis Medicines closed a $670m IPO just two months later to support its bid to bring ‘helicon’ peptides to the oncology market.
With several US biotechs securing high-value IPOs since the beginning of 2026, it appears that the sector is currently weathering the storm driven by global geopolitical shifts and macroeconomic policy changes in the US.
